About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Key Takeaways Moderna lowered its full-year guidance as falling European demand and a difficult U.S. market limited sales of its COVID-19 vaccine. The company reported a second quarter loss and a 30% drop in revenue. The stock tumbled, dropping into negative territory for the year. Moderna (MRNA) shares plunged after the COVID-19 vaccine maker slashed its outlook on lower demand in Europe and a tough market in the U.S. The company now expects full-year product revenue of $3 billion to $3.5 billion, down fro ...

The drugmaker is facing problems in the U.S. and abroad Moderna Inc (NASDAQ:MRNA) stock is freefalling this morning, last seen down 15.2% to trade at $95.48 and pacing for its worst day since November 2021 after the company's second-quarter financial results. The drugmaker reported revenue and losses that beat Wall Street's estimates, but also lowered its full-year sales guidance due to problems stateside and abroad. Specifically, Moderna is facing increased competition for respiratory vaccines in the U.S. ...

Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.03%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.59 per share when it actually produced a loss of $3.07, delivering a surprise of 14.48%. Over the last four quarters, the company has s ...

The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a "competitive environment" for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 billion, down from a previous guidance of $4 ...

Exhibit 99.1 Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announ ...

During a recent fireside chat at the Goldman Sachs (GS) Healthcare Conference in June, Moderna's President Stephen Hoge told the audience: as we've articulated, including our last R&D Day, there are really four pillars where we think our technology is mature and we're scaling, we call them modalities. The first is respiratory vaccines. The second is vaccines against other viruses, so latent viruses, and other infections. The third is our work in oncology, principally around our INT program with Merck. And t ...

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. The consensus estimate for 'Revenue- Product sales' stands at $102.49 million. The estimate indicates ...

Moderna (MRNA) will report second-quarter earnings on Aug 1, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $124.9 million and a loss of $3.47 per share, respectively. Both metrics indicate significant declines from the year-ago quarter's levels. MRNA's loss estimates have remained consistent at $7.46 per share for 2024 and $5.29 for 2025 in the past 30 days. | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|--- ...

MRNA Stock Outperforms Industry, Sector & S&P 500 Encouraging Upcoming Launches Moderna (MRNA) has risen 22.1% in the year-to-date period against the industry's 2.7% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average. Image Source: Zacks Investment Research Despite registering a significant fall in top-line due to lower COVID-19 vaccine sales, Moderna's shares continue to soar this year on the ...